Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer

Pathol Int. 2015 Nov;65(11):569-74. doi: 10.1111/pin.12343. Epub 2015 Sep 2.

Abstract

Human leukocyte antigen (HLA)-F is one of the non-classical HLA class I molecules that protects the fetus in pregnancy. HLA-F expression was immunohistochemically examined and the association between clinical parameters and HLA-F expression was analyzed. Cancerous HLA-F and stromal HLA-F-positive infiltrating cells were detected in 91 (40.0%) and 186 (81.6%) cases, respectively. HLA-F positivity in cancer cells was significantly associated with tumor size (P < 0.05). There was a weak correlation between HLA-F positivity of cancer cells and HLA-F positive infiltrative cells (P < 0.01, r = 0.11). HLA-F positivity did not affect patients' survival in 209 breast cancer. However, confined to stage II breast cancer, the HLA-F positive group showed significantly poorer outcomes than the HLA-F negative group (P < 0.05). The present study provides the first evidence that HLA-F positivity in breast carcinoma affects clinicopathological factors and could be selected as a prognostic marker for limited clinical stage.

Keywords: HLA-F; breast cancer; clinical stage; tumor infiltrating cells.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / immunology
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / immunology
  • Breast Neoplasms / metabolism*
  • Female
  • Histocompatibility Antigens Class I / immunology
  • Histocompatibility Antigens Class I / metabolism*
  • Humans
  • Leukocytes / cytology*
  • Leukocytes / immunology
  • Lymphatic Metastasis
  • Middle Aged
  • Prognosis

Substances

  • Biomarkers, Tumor
  • HLA-F antigens
  • Histocompatibility Antigens Class I